Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin

doi:10.1084/jem.180.3.1047

This Article

	Full Text (PDF, 1026K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Grzegorzewski, K.
	Articles by Wiltrout, R. H.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Grzegorzewski, K.
	Articles by Wiltrout, R. H.


Social Bookmarking

	What's this?

ARTICLES

Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin

K Grzegorzewski, FW Ruscetti, N Usui, G Damia, DL Longo, JA Carlino, JR Keller and RH Wiltrout
Biological Carcinogenesis and Development Program, PRI/DynCorp, Frederick, Maryland.

Transforming growth factor beta 1 (TGF-beta 1) and TGF-beta 2 can reversibly inhibit the proliferation of hematopoietic progenitor cells in vivo, leading us to hypothesize that such quiescent progenitors might be more resistant to high doses of cell cycle active chemotherapeutic drugs, thereby allowing dose intensification of such agents. Initial studies showed that whereas administration of TGF-beta 1 or TGF-beta 2 did not prevent death in normal mice treated with high doses of 5-fluorouracil (5-FU), those mice that received TGF-beta 2 did exhibit the beginning of a hematologic recovery by day 11 after administration of 5-FU, and were preferentially rescued by a suboptimal number of transplanted bone marrow cells. Subsequently, it was found that the administration of TGF-beta 2 protected recovering progenitor cells from high concentrations of 5-FU in vitro. This protection coincided with the finding that significantly more progenitors for colony-forming unit-culture (CFU-c) and CFU-granulocyte, erythroid, megakaryocyte, macrophage (GEMM) were removed from S-phase by TGF-beta in mice undergoing hematopoietic recovery than in normal mice. Further studies showed that the administration of TGF-beta protected up to 90% of these mice undergoing hematologic recovery from a rechallenge in vivo with high dose 5-FU, while survival in mice not given TGF-beta was < 40%. Pretreatment of mice with TGF-beta 1 or TGF-beta 2 also protected 70-80% of mice from lethal doses of the noncycle active chemotherapeutic drug, doxorubicin hydrochloride (DXR). These results demonstrate that TGF-beta can protect mice from both the lethal hematopoietic toxicity of 5-FU, as well as the nonhematopoietic toxicity of DXR. This report thus shows that a negative regulator of hematopoiesis can be successfully used systemically to mediate chemoprotection in vivo.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Charrier, S., Michaud, A., Badaoui, S., Giroux, S., Ezan, E., Sainteny, F., Corvol, P., Vainchenker, W. (2004). Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. Blood 104: 978-985 [Abstract] [Full Text]
Wang, H., Li, M., Rinehart, J. J., Zhang, R. (2004). Pretreatment with Dexamethasone Increases Antitumor Activity of Carboplatin and Gemcitabine in Mice Bearing Human Cancer Xenografts: In Vivo Activity, Pharmacokinetics, and Clinical Implications for Cancer Chemotherapy. Clin. Cancer Res. 10: 1633-1644 [Abstract] [Full Text]
Blagosklonny, M. V., Pardee, A. B. (2001). Exploiting Cancer Cell Cycling for Selective Protection of Normal Cells. Cancer Res. 61: 4301-4305 [Abstract] [Full Text]
Satterwhite, D. J., White, R. L., Matsunami, N., Neufeld, K. L. (2000). Inhibition of Topoisomerase II{{alpha}} Expression by Transforming Growth Factor-{beta}1 Is Abrogated by the Papillomavirus E7 Protein. Cancer Res. 60: 6989-6994 [Abstract] [Full Text]
Fortunel, N. O., Hatzfeld, A., Hatzfeld, J. A. (2000). Transforming growth factor-beta : pleiotropic role in the regulation of hematopoiesis. Blood 96: 2022-2036 [Abstract] [Full Text]
Cheng, T., Rodrigues, N., Shen, H., Yang, Y., Dombkowski, D., Sykes, M., Scadden, D. T. (2000). Hematopoietic Stem Cell Quiescence Maintained by p21cip1/waf1. Science 287: 1804-1808 [Abstract] [Full Text]
Batard, P, Monier, M., Fortunel, N, Ducos, K, Sansilvestri-Morel, P, Phan, T, Hatzfeld, A, Hatzfeld, J. (2000). TGF-(beta)1 maintains hematopoietic immaturity by a reversible negative control of cell cycle and induces CD34 antigen up-modulation. J. Cell Sci. 113: 383-390 [Abstract]
Masse, A., Ramirez, L.H., Bindoula, G., Grillon, C., Wdzieczak-Bakala, J., Raddassi, K., Deschamps de Paillette, E., Mencia-Huerta, J.M., Koscielny, S., Potier, P., Sainteny, F., Carde, P. (1998). The Tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (Goralatide) Protects From Doxorubicin-Induced Toxicity: Improvement in Mice Survival and Protection of Bone Marrow Stem Cells and Progenitors. Blood 91: 441-449 [Abstract] [Full Text]
Han, Z. C., Lu, M., Li, J., Defard, M., Boval, B., Schlegel, N., Caen, J. P. (1997). Platelet Factor 4�and Other CXC Chemokines Support the Survival of Normal Hematopoietic Cells and Reduce the Chemosensitivity of Cells to Cytotoxic Agents. Blood 89: 2328-2335 [Abstract] [Full Text]